PL3484514T3 - Kompozycje i sposoby związane z projektowanymi konstruktami Fc - Google Patents

Kompozycje i sposoby związane z projektowanymi konstruktami Fc

Info

Publication number
PL3484514T3
PL3484514T3 PL17803463.3T PL17803463T PL3484514T3 PL 3484514 T3 PL3484514 T3 PL 3484514T3 PL 17803463 T PL17803463 T PL 17803463T PL 3484514 T3 PL3484514 T3 PL 3484514T3
Authority
PL
Poland
Prior art keywords
engineered
constructs
compositions
methods related
methods
Prior art date
Application number
PL17803463.3T
Other languages
English (en)
Inventor
Carlos J. Bosques
Jonathan C. Lansing
Daniel ORTIZ
Laura RUTITZKY
Nathanial J. Washburn
Original Assignee
Momenta Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals, Inc. filed Critical Momenta Pharmaceuticals, Inc.
Publication of PL3484514T3 publication Critical patent/PL3484514T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Prostheses (AREA)
PL17803463.3T 2016-05-23 2017-05-23 Kompozycje i sposoby związane z projektowanymi konstruktami Fc PL3484514T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US201762443451P 2017-01-06 2017-01-06
PCT/US2017/034084 WO2017205434A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Publications (1)

Publication Number Publication Date
PL3484514T3 true PL3484514T3 (pl) 2024-04-29

Family

ID=60412547

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17803463.3T PL3484514T3 (pl) 2016-05-23 2017-05-23 Kompozycje i sposoby związane z projektowanymi konstruktami Fc

Country Status (14)

Country Link
US (4) US11155640B2 (pl)
EP (2) EP3484514B1 (pl)
JP (5) JP7045333B6 (pl)
KR (3) KR102590061B1 (pl)
CN (4) CN118206639A (pl)
AU (2) AU2017272111B2 (pl)
BR (2) BR112018074032A2 (pl)
CA (2) CA3025310A1 (pl)
DK (1) DK3484514T3 (pl)
ES (1) ES2973251T3 (pl)
IL (3) IL309293A (pl)
PL (1) PL3484514T3 (pl)
SG (3) SG11201810466PA (pl)
WO (2) WO2017205436A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
PL3484514T3 (pl) 2016-05-23 2024-04-29 Momenta Pharmaceuticals, Inc. Kompozycje i sposoby związane z projektowanymi konstruktami Fc
BR112019013955A2 (pt) 2017-01-06 2020-02-11 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos de fc manipulados
CN112969717A (zh) * 2018-07-11 2021-06-15 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
WO2020014505A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
EP3820516A4 (en) * 2018-07-11 2022-04-20 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO MANIPULATED FC ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
KR20210042326A (ko) * 2018-07-11 2021-04-19 모멘타 파머슈티컬스 인코포레이티드 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
MX2021000306A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4.
CA3105985A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
BR112021000388A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado
AU2019299935A1 (en) * 2018-07-11 2021-02-18 Inc. Momenta Pharmaceuticals Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to PD-L1
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
BR112022003713A2 (pt) 2019-09-13 2022-08-09 CSL Behring Lengnau AG Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
CN114786721B (zh) 2019-12-06 2025-10-17 康诺贝林伦瑙有限公司 Fc多聚体的稳定组合物
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
US12103961B2 (en) * 2020-12-07 2024-10-01 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use
WO2024206820A1 (en) * 2023-03-30 2024-10-03 Dna Twopointo, Inc. Fc engineering for heterodimeric antibody format

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0975355A2 (en) 1996-06-14 2000-02-02 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
MX367012B (es) 2007-06-01 2019-08-02 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
PL2247304T3 (pl) 2008-04-02 2017-01-31 Macrogenics, Inc. Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
WO2010085682A2 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US20120064008A1 (en) 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
WO2011008517A2 (en) * 2009-06-30 2011-01-20 Research Development Foundation Immunoglobulin fc polypeptides
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
CN102666874B (zh) 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
AU2010321720B2 (en) 2009-11-23 2017-03-02 Amgen Inc. Monomeric antibody Fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
WO2012020096A1 (en) 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2654780B1 (en) * 2010-12-23 2017-02-01 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
CN103429619B (zh) 2011-03-17 2017-07-28 雷蒙特亚特特拉维夫大学有限公司 双特异性和单特异性、不对称抗体和其制备方法
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
AU2012332021B8 (en) * 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2858659B1 (en) * 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
TW201402611A (zh) 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
EP2885320A4 (en) 2012-08-20 2016-04-06 Gliknik Inc MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY
AU2012392760C1 (en) 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN104558194B (zh) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
WO2015095684A1 (en) 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
CA2931979A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding properties
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
JP6851199B2 (ja) 2014-03-05 2021-03-31 ユーシービー バイオファルマ エスアールエル 多量体Ｆｃタンパク質
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
CN106255704A (zh) 2014-04-16 2016-12-21 Ucb生物制药私人有限公司 多聚体Fc蛋白
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
TWI742423B (zh) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
PL3484514T3 (pl) 2016-05-23 2024-04-29 Momenta Pharmaceuticals, Inc. Kompozycje i sposoby związane z projektowanymi konstruktami Fc
BR112019013955A2 (pt) 2017-01-06 2020-02-11 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos de fc manipulados

Also Published As

Publication number Publication date
NZ749292A (en) 2025-08-29
EP3464376A4 (en) 2020-03-18
EP3464376A1 (en) 2019-04-10
WO2017205436A1 (en) 2017-11-30
IL263211B2 (en) 2023-09-01
BR112018074056A2 (pt) 2019-03-06
US12297291B2 (en) 2025-05-13
IL263213A (en) 2018-12-31
JP7045333B6 (ja) 2022-05-06
KR102635635B1 (ko) 2024-02-14
NZ749279A (en) 2025-08-29
IL263213B1 (en) 2024-01-01
SG11201810466PA (en) 2018-12-28
US20210221917A1 (en) 2021-07-22
IL263211A (en) 2018-12-31
AU2017272109A1 (en) 2019-01-17
ES2973251T3 (es) 2024-06-19
IL263211B1 (en) 2023-05-01
IL309293A (en) 2024-02-01
JP2022068176A (ja) 2022-05-09
US20220049019A1 (en) 2022-02-17
CA3025306A1 (en) 2017-11-30
EP3484514A4 (en) 2020-08-12
KR20220151025A (ko) 2022-11-11
KR102590061B1 (ko) 2023-10-18
CA3025310A1 (en) 2017-11-30
KR102462084B1 (ko) 2022-11-02
JP2019519527A (ja) 2019-07-11
JP7295301B2 (ja) 2023-06-20
KR20190021255A (ko) 2019-03-05
AU2017272111A1 (en) 2019-01-17
CN109963869A (zh) 2019-07-02
CN109789203A (zh) 2019-05-21
SG11201810465RA (en) 2018-12-28
US11623964B2 (en) 2023-04-11
CN116063540A (zh) 2023-05-05
US11155640B2 (en) 2021-10-26
CN109789203B (zh) 2022-08-05
DK3484514T3 (da) 2024-01-29
AU2017272109B2 (en) 2024-07-25
AU2017272111B2 (en) 2024-05-16
JP2025026880A (ja) 2025-02-26
JP7045333B2 (ja) 2022-03-31
JP2022095685A (ja) 2022-06-28
JP2019519528A (ja) 2019-07-11
US20240067757A1 (en) 2024-02-29
KR20190026684A (ko) 2019-03-13
IL263213B2 (en) 2024-05-01
EP3484514B1 (en) 2023-12-06
BR112018074032A2 (pt) 2019-02-26
WO2017205434A1 (en) 2017-11-30
SG10202011624SA (en) 2021-01-28
EP3484514A1 (en) 2019-05-22
US20190284305A1 (en) 2019-09-19
CN118206639A (zh) 2024-06-18

Similar Documents

Publication Publication Date Title
IL286367A (en) Compositions and methods relating to engineered fc constructs
IL263211A (en) Compositions and methods relating to engineered fc constructs
IL257307B (en) Transgenic crispr–cas9 preparations and methods of use
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
ZA201702794B (en) Cellulose-containing compositions and methods of making same
EP3134130A4 (en) Compositions and methods to treating hemoglobinopathies
ZA201701909B (en) Trichoderma compositions and methods of use
SG10202107391YA (en) Compositions and methods related to engineered fc constructs
EP3119421A4 (en) Engineered chimeric pegylated adi and methods of use
IL234929A0 (en) Preparations containing liposomes and their use to prevent infections
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
GB201421430D0 (en) Antibodies to Adam17 and uses thereof
HK40006234A (en) Compositions and methods related to engineered fc constructs
HK40017020A (en) Compositions and methods related to engineered fc constructs